Reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".
作者信息
Rydberg Michael G
机构信息
Division of Geriatric Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
Alzheimers Dement. 2025 Feb;21(2):e14620. doi: 10.1002/alz.14620.
Abstract
摘要
相似文献
1
Reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对《司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟》的回复
Alzheimers Dement. 2025 Feb;21(2):e14620. doi: 10.1002/alz.14620.
2
Response to the letter titled reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对题为《司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟》的信件的回复
Alzheimers Dement. 2025 Feb;21(2):e14611. doi: 10.1002/alz.14611.
3
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
4
Generating real-world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti-amyloid therapies.在早期阿尔茨海默病中生成真实世界证据：应用目标试验模拟框架研究抗淀粉样蛋白疗法安全性的考量
Alzheimers Dement (N Y). 2025 Apr 15;11(2):e70080. doi: 10.1002/trc2.70080. eCollection 2025 Apr-Jun.
5
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.在 2 型糖尿病患者中，司美格鲁肽与烟草使用障碍的关联：使用真实世界数据的目标试验模拟。
Ann Intern Med. 2024 Aug;177(8):1016-1027. doi: 10.7326/M23-2718. Epub 2024 Jul 30.
6
Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.从真实世界的利用数据看肥胖和 2 型糖尿病患者中司美格鲁肽的使用：美国全民健康研究计划的分析。
Diabetes Obes Metab. 2024 Nov;26(11):4989-4995. doi: 10.1111/dom.15911. Epub 2024 Sep 9.
7
Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice.口服司美格鲁肽治疗2型糖尿病的真实世界证据。临床实践的叙述性综述
Clin Ther. 2025 Jan;47(1):102-110. doi: 10.1016/j.clinthera.2024.11.005. Epub 2024 Nov 29.
8
Response to the letter titled "Analysis of semaglutide's effect on Alzheimer's disease risk".对题为“司美格鲁肽对阿尔茨海默病风险的影响分析”的信件的回复。
Alzheimers Dement. 2025 Feb;21(2):e14509. doi: 10.1002/alz.14509. Epub 2025 Jan 14.
9
Insight into the etiology of Alzheimer's disease from GLP-1R knockout mice: Commentary on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes".从胰高血糖素样肽-1受体基因敲除小鼠看阿尔茨海默病的病因：评“司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联”
Alzheimers Dement. 2025 Feb;21(2):e70033. doi: 10.1002/alz.70033.
10
High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data.基于真实世界数据的阿尔茨海默病药物再利用的高通量目标试验模拟。
Nat Commun. 2023 Dec 11;14(1):8180. doi: 10.1038/s41467-023-43929-1.
本文引用的文献
1
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
2
Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast.在观察性研究中检测选择偏倚——当干预起效过快时。
JAMA Intern Med. 2023 Sep 1;183(9):897-898. doi: 10.1001/jamainternmed.2023.2067.
3
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究：阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
Zotero 插件